Skip to Main Content

Print | Bookmark | Font Size: + |

References for GI Risk Stratification

Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of G. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2016;111(1):30-50; quiz 51.

American Gastroenterological A, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011;140(3):1084-1091.

Asge Standards of Practice C, Qumseya B, Sultan S, et al. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019;90(3):335-359 e332.

Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63(1):7-42.

Konda VJA, Souza RF. Barrett's Esophagus and Esophageal Carcinoma: Can Biomarkers Guide Clinical Practice? Curr Gastroenterol Rep. 2019;21(4):14.

Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus. Gastrointest Endosc. 2019;90(5):707-717 e701.

Dam AN, Klapman J. A narrative review of Barrett's esophagus in 2020, molecular and clinical update. Ann Transl Med. 2020;8(17):1107.

Souza RF, Spechler SJ. Advances in Biomarkers for Risk Stratification in Barrett's Esophagus. Gastrointest Endosc Clin N Am. 2021;31(1):105-115.

Iyer PG, Katzka DA. Nonendoscopic Detection of Barrett Esophagus and Esophageal Adenocarcinoma: Recent Advances and Implications. Ann Intern Med. 2021;174(7):1006-1007.

Kolb JM, Wani S. A Paradigm Shift in Screening for Barrett's Esophagus: The BEST Is Yet to Come. Gastroenterology. 2021;160(1):467-469.

Yusuf A, Fitzgerald RC. Screening for Barrett's Oesophagus: Are We Ready for it? Curr Treat Options Gastroenterol. 2021:1-16. 

Offman J, Fitzgerald RC. Alternatives to Traditional Per-Oral Endoscopy for Screening. Gastrointest Endosc Clin N Am. 2017;27(3):379-396.

Ross-Innes CS, Chettouh H, Achilleos A, et al. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol. 2017;2(1):23-31.

Moinova HR, LaFramboise T, Lutterbaugh JD, et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. Sci Transl Med. 2018;10(424).

Iyer PG, Taylor WR, Johnson ML, et al. Highly Discriminant Methylated DNA Markers for the Non-endoscopic Detection of Barrett's Esophagus. Am J Gastroenterol. 2018;113(8):1156-1166.

Chettouh H, Mowforth O, Galeano-Dalmau N, et al. Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. Gut. 2018;67(11):1942-1949.

Wang Z, Kambhampati S, Cheng Y, et al. Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study. Clin Cancer Res. 2019;25(7):2127-2135.

Fitzgerald RC, di Pietro M, O'Donovan M, et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet. 2020;396(10247):333-344.

Iyer PG, Taylor WR, Johnson ML, et al. Accurate Nonendoscopic Detection of Barrett's Esophagus by Methylated DNA Markers: A Multisite Case Control Study. Am J Gastroenterol. 2020;115(8):1201-1209.

Iyer PG, Taylor WR, Slettedahl SW, et al. Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrett's esophagus in a multisite case-control study. Gastrointest Endosc. 2021.

Heberle CR, Omidvari AH, Ali A, et al. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. Clin Gastroenterol Hepatol. 2017;15(9):1397-1404 e1397.

Swart N, Maroni R, Muldrew B, et al. Economic evaluation of Cytosponge(R)-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data. EClinicalMedicine. 2021;37:100969.

Sami SS, Moriarty JP, Rosedahl JK, et al. Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening. Am J Gastroenterol. 2021.

spacer

26 Century Blvd Ste ST610, Nashville, TN 37214-3685 © CGS Administrators, LLC. All Rights Reserved